Technical Analysis for CSSPF - Circassia Pharmaceutical Plc

Grade Last Price % Change Price Change
grade D 0.246 -7.17% -0.0190
CSSPF closed down 7.17 percent on Friday, November 8, 2019, on 1.34 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
See historical CSSPF trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish -7.17%
Volume Surge Other -7.17%
Wide Bands Range Expansion -7.17%
Wide Bands Range Expansion -5.38%
Gapped Down Weakness -5.38%
New Downtrend Bearish -12.14%
Older signals for CSSPF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. The company's asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide. It is also developing various novel specialty treatments for COPD, including Spiriva substitute, Novel LABA/LAMA formulation, and novel COPD therapy formulation. In addition, the company' development pipeline includes a range of treatments for allergies, such as cat allergy, grass allergy, house dust mite allergy, and ragweed allergy. It has a collaboration agreement with AstraZeneca to promote Tudorza for COPD treatment, and has the US commercial rights to late-stage COPD product Duaklir. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.
Medicine Medical Specialties RTT Biopharmaceutical Clinical Medicine Alcohols Asthma Chronic Obstructive Pulmonary Disease Allergies Respiratory Diseases Astrazeneca Chronic Lower Respiratory Diseases Combination Drugs Treatment Of Asthma And Chronic Obstructive Pulmonary Disease Copd

Is CSSPF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.3
52 Week Low 0.199
Average Volume 46,725
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.2564
10-Day Moving Average 0.2629
Average True Range 0.0571
ADX 46.51
+DI 25.3215
-DI 67.6864
Chandelier Exit (Long, 3 ATRs ) 0.2487
Chandelier Exit (Short, 3 ATRs ) 0.3703
Upper Bollinger Band 0.3229
Lower Bollinger Band 0.1899
Percent B (%b) 0.42
BandWidth 51.8721
MACD Line -0.1710
MACD Signal Line -0.1889
MACD Histogram 0.0179
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.2460
Resistance 3 (R3) 0.2460 0.2460 0.2460
Resistance 2 (R2) 0.2460 0.2460 0.2460 0.2460
Resistance 1 (R1) 0.2460 0.2460 0.2460 0.2460 0.2460
Pivot Point 0.2460 0.2460 0.2460 0.2460 0.2460
Support 1 (S1) 0.2460 0.2460 0.2460 0.2460 0.2460
Support 2 (S2) 0.2460 0.2460 0.2460 0.2460
Support 3 (S3) 0.2460 0.2460 0.2460
Support 4 (S4) 0.2460